Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Bowden

Showing results (91-100 of 95) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 95 results.
Gastroenterology|January 25, 2011
Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAGAnn D Kwong, Isabel Najera, Jill Bechtel, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 15, 2024
High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapySimon J Hume, Danny K Wong, Man-Fung Yuen, et al.
The Journal of Infectious Diseases|September 15, 2022
Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling PathwaysSamuel A L Hall, Gareth S Burns, Benjamin J Mooney, et al.
Hepatology Communications|July 17, 2023
Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participantsAlexander J Thompson, Kathy Jackson, Sara Bonanzinga, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 5, 2020
Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure CharacteristicsTimothy Papaluca, Stuart K Roberts, Simone I Strasser, et al.
Pageof 10

Showing results (91-100 of 95) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 95 results.
Gastroenterology|January 25, 2011
Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAGAnn D Kwong, Isabel Najera, Jill Bechtel, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 15, 2024
High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapySimon J Hume, Danny K Wong, Man-Fung Yuen, et al.
The Journal of Infectious Diseases|September 15, 2022
Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling PathwaysSamuel A L Hall, Gareth S Burns, Benjamin J Mooney, et al.
Hepatology Communications|July 17, 2023
Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participantsAlexander J Thompson, Kathy Jackson, Sara Bonanzinga, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 5, 2020
Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure CharacteristicsTimothy Papaluca, Stuart K Roberts, Simone I Strasser, et al.
Pageof 10